CCIVI works to address the significant policy, investment, leadership, and organizational barriers that must be overcome to develop the next generation of influenza vaccines that can protect those most at risk of serious illness and death and reduce the global impact of the next influenza pandemic.
The first phase of this initiative was to review all aspects of 2009-2010 pandemic A(H1N1)pdm09 influenza vaccine preparedness and response and to review the scientific and programmatic basis for the current seasonal influenza vaccine efforts. The final report, published October 15, 2012, is a review of more than 12,000 publications, documents, transcripts and notes dating back to 1936 and interviews and follow-up with 88 experts in influenza vaccine research, development, and use.
The findings from the first phase of this initiative form the basis of the goals in phase two. The second phase, currently under development, is a 3‐year project designed with two specific goals: (1) develop specific solutions necessary to advance the vaccine enterprise toward a new generation of vaccines and (2) identify responsible organizations for implementation of solutions to existing barriers. These goals will be accomplished by engaging the foremost international experts through a working Forum on Influenza Vaccines.
The first phase of this initiative launched in 2009 with a generous grant from the Alfred P. Sloan Foundation.